Medicina Interna II Divisione di Ematologia, Ospedale S. Luigi Gonzaga
Welcome,         Profile    Billing    Logout  
 10 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cilloni, Daniela
AMELIORATE, NCT04174612: AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Recruiting
3
172
Europe
Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia With FLT3/ITD Mutation
12/22
08/25
NCT04168502: Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting
3
414
Europe
Glasdegib, Gemtuzumab Ozogamicin
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia
04/24
04/27
ACROBAT, NCT04184505: Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS

Recruiting
3
274
Europe
Azacitidine, AZA, Standard Chemotherapy, STD CHT, Allogeneic stem cell transplantation, HSCT
Gruppo Italiano Malattie EMatologiche dell'Adulto
High-risk MDS
03/24
03/24
MYLOX-1, NCT04679870: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

Active, not recruiting
2
21
Europe, US, RoW
GB2064
Galecto Biotech AB, OPIS s.r.l
Myelofibrosis
12/23
06/26
NCT05306301: Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

Recruiting
2
32
Europe
Ponatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chemotherapy, Leukemia, Acute Lymphoblastic
02/25
07/28
IDIOME-STUDY, NCT03503409: IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

Active, not recruiting
2
68
Europe
AG-120
Groupe Francophone des Myelodysplasies
Myelodysplastic Syndromes, Acute Myeloid Leukemia
04/25
04/25
1621-QLG-LG, NCT03755856: Long-term Outcomes for Acute Myeloid Leukemia Patients

Recruiting
N/A
343
Europe, RoW
Questionnaire
Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia
06/21
12/22
NCT03789981: Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia

Recruiting
N/A
75
Europe
Immunogenic profile
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Acute Myeloid Leukemia
12/21
12/21
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
10/22
10/22
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Recruiting
N/A
104
Europe
Venetoclax plus HMA
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia
12/22
12/23
FISiM-Luspa, NCT05520749: Efficacy and Safety of Luspatercept: A Study by Fondazione Italiana Sindromi Mielodisplastiche

Completed
N/A
215
Europe
Luspatercept
Fondazione Italiana Sindromi Mielodisplastiche-ETS, Istituto Clinico Humanitas
Myeloid Dysplasia
12/22
01/23
NCT04460950: Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms

Recruiting
N/A
237
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia, Familial Acute Myeloid Leukemia, Myelodysplastic Syndromes
03/25
03/25
NCT05553873: Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.

Recruiting
N/A
500
Europe
University of Milano Bicocca
Myeloproliferative Disease, Inflammatory Markers
12/26
12/26

Download Options